

09/582296

529 Rec'd PCT/PTO 23 JUN 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING NATIONAL PHASE OF
PCT APPLICATION UNDER 35 U.S.C. 371 AND 37 CFR 1.494 OR 1.495

To: Asst. Commissioner of Patents
 and Trademarks
 Washington, D.C. 20231

(Our Deposit Account No. 03-3975)

TRANSMITTAL LETTER TO THE UNITED STATES
 DESIGNATED/ELECTED OFFICE (DO/EO/US)

Atty Dkt: PM 270652 /F 7418 (C)
M# /Client Ref.

From: Pillsbury Madison & Sutro LLP, IP Group:

Date: June 23, 2000

This is a **REQUEST** for **FILING** a PCT/USA National Phase Application based on:

1. International Application <u>PCT/EP98/08554</u> ↑ country code	2. International Filing Date 23 December 1998 Day MONTH Year	3. Earliest Priority Date Claimed 22 January 1998 Day MONTH Year (use item 2 if no earlier priority)
---	--	---

4. Measured from the earliest priority date in item 3, this PCT/USA National Phase Application Request is being filed within:

(a) ☐ 20 months from above item 3 date (b) ☒ 30 months from above item 3 date,

(c) Therefore, the due date (unextendable) is July 22, 2000

5. Title of Invention FROZEN FOOD PRODUCT

6. Inventor(s) SIDEBOTTOM, Christopher Michael et al

Applicant herewith submits the following under 35 U.S.C. 371 to effect filing:

7. ☒ Please immediately start national examination procedures (35 U.S.C. 371 (f)).

8. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (file if in English but, if in foreign language, file only if not transmitted to PTO by the International Bureau) including:

- a. ☒ Request;
 b. ☒ Abstract;
 c. 18 pgs. Spec. and Claims;
 d. sheet(s) Drawing which are ☐ informal ☐ formal of size ☐ A4 ☐ 11"

9. ☒ A copy of the International Application has been transmitted by the International Bureau.

10. A translation of the International Application into English (35 U.S.C. 371(c)(2))

- a. ☐ is transmitted herewith including: (1) ☐ Request; (2) ☐ Abstract;
 (3) pgs. Spec. and Claims;
 (4) sheet(s) Drawing which are:
☐ informal ☐ formal of size ☐ A4 ☐ 11"
- b. ☐ is not required, as the application was filed in English.
 c. ☐ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
 d. ☐ Translation verification attached (not required now).

RE: USA National Filing of PCT/EP98/08554

534 Rec'd PCT/PTC 23 JUN 2000

11. ☒ **PLEASE AMEND** the specification before its first line by inserting as a separate paragraph:
- a. ☒ --This application is the national phase of international application PCT/EP98/08554 filed December 23, 1998 which designated the U.S.--
- b. ☐ --This application also claims the benefit of U.S. Provisional Application No. 60/____, filed ____--
12. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., **before 18th month from first priority date above in item 3, are transmitted herewith (file only if in English) including:**
13. ☒ PCT Article 19 claim amendments (if any) have been transmitted by the International Bureau
14. ☐ Translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., of **claim amendments** made before 18th month, is attached (**required by 20th month from the date in item 3 if box 4(a) above is X'd, or 30th month if box 4(b) is X'd, or else amendments will be considered canceled**).
15. **A declaration of the inventor** (35 U.S.C. 371(c)(4))
- a. ☐ is submitted herewith ☐ Original ☐ Facsimile/Copy
- b. ☒ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
16. **An International Search Report (ISR):**
- a. Was prepared by ☒ European Patent Office ☐ Japanese Patent Office ☐ Other
- b. ☒ has been transmitted by the international Bureau to PTO.
- c. ☒ copy herewith (2 pg(s).) ☒ plus Annex of family members (1 pg(s).).
17. **International Preliminary Examination Report (IPER):**
- a. ☒ has been transmitted (if this letter is filed after 28 months from date in item 3) in English by the International Bureau with Annexes (if any) in original language.
- b. ☒ copy herewith in English.
- c.1 ☐ IPER Annex(es) in original language ("Annexes" are amendments made to claims/spec/drawings during Examination) including attached amended:
- c.2 ☐ Specification/claim pages #____ claims #
Dwg Sheets #
- d. ☐ Translation of Annex(es) to IPER (**required by 30th month due date, or else annexed amendments will be considered canceled**).
18. **Information Disclosure Statement** including:
- a. ☒ Attached Form PTO-1449 listing documents
- b. ☐ Attached copies of documents listed on Form PTO-1449
- c. ☒ A concise explanation of relevance of ISR references is given in the ISR.
19. ☐ **Assignment** document and Cover Sheet for recording are attached. Please mail the recorded assignment document back to the person whose signature, name and address appear at the end of this letter.
20. ☐ Copy of Power to IA agent.
21. ☐ **Drawings** (complete only if 8d or 10a(4) not completed): ____ sheet(s) per set: ☐ 1 set informal;
☐ Formal of size ☐ A4 ☐ 11"
22. ☐ ____ (No.) **Verified Statement(s)** establishing "small entity" status under Rules 9 & 27
23. **Priority** is hereby claimed under 35 U.S.C. 119/365 based on the priority claim and the certified copy, both filed in the International Application during the international stage based on the filing in (country) GREAT BRITAIN of:
- | | Application No. | Filing Date | | Application No. | Filing Date |
|-----|-----------------|------------------|-----|-----------------|-------------|
| (1) | 9801420.2 | January 22, 1998 | (2) | _____ | _____ |
| (3) | _____ | _____ | (4) | _____ | _____ |
| (5) | _____ | _____ | (6) | _____ | _____ |
- a. ☒ See Form PCT/IB/304 sent to US/DO with copy of priority documents. If copy has not been received, please proceed promptly to obtain same from the IB.
- b. ☐ Copy of Form PCT/IB/304 attached.

RE: USA National Filing of PCT/EP98/08554

534 Rec'd PCT/PTO 23 JUN2000

24. Attached:

25. Preliminary Amendment:

25.5 Per Item 17.c2, cancel original pages #_____, claims #_____, Drawing Sheets #26. **Calculation of the U.S. National Fee (35 U.S.C. 371 (c)(1)) and other fees is as follows:**Based on amended claim(s) per above item(s) ☐ 12, ☐ 14, ☐ 17, ☐ 25, ☐ 25.5 (hilitte)

Total Effective Claims	minus 20 =	x \$18/\$9	= \$0	966/967
Independent Claims	minus 3 =	x \$78/\$39	= \$0	964/965
If any proper (ignore improper) Multiple Dependent claim is present,		add\$260/\$130	+0	968/969

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(4)): →→ BASIC FEE REQUIRED, NOW →→→→

A. If country code letters in item 1 are not "US", "BR", "BB", "TT", "MX", "IL", "NZ", "IN" or "ZA"

See item 16 re:

1. Search Report was <u>not prepared</u> by EPO or JPO -----	add\$970/\$485		960/961
2. Search Report was prepared by EPO or JPO -----	add\$840/\$420	+840	970/971

SKIP B, C, D AND E UNLESS country code letters in item 1 are "US", "BR", "BB", "TT", "MX", "IL", "NZ", "IN" or "ZA"

→ <input type="checkbox"/> B. If <u>USPTO</u> did not issue <u>both</u> International Search Report (ISR) <u>and</u> (if box 4(b) above is X'd) the International Examination Report (IPER), -----	add\$970/\$485	+0	960/961
(only) → <input type="checkbox"/> C. If <u>USPTO</u> issued ISR but not IPER (or box 4(a) above is (one) X'd), -----	add\$690/\$345	+0	958/959
(of) (these) → <input type="checkbox"/> D. If <u>USPTO</u> issued IPER but IPER Sec. V boxes <u>not all</u> 3 (4) YES, -----	add\$670/\$335	+0	956/957
(boxes) → <input type="checkbox"/> E. If international preliminary examination fee was paid to <u>USPTO</u> and Rules 492(a)(4) and 496(b) <u>satisfied</u> (IPER Sec. V <u>all</u> 3 boxes YES for <u>all</u> claims), -----	add \$96/\$48	+0	962/963

27. SUBTOTAL = \$840

28. If Assignment box 19 above is X'd, add Assignment Recording fee of ---\$40 +0 (581)

29. Attached is a check to cover the ----- TOTAL FEES \$840

Our Deposit Account No. 03-3975

Our Order No. 60113

270652

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 and 492 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filedPillsbury Madison & Sutro LLP
Intellectual Property Group1100 New York Avenue, NW
Ninth Floor
Washington, DC 20005-3918
Tel: (202) 861-3000
Atty/Sec: PNK/mhn

By Atty: Paul N. Kokulis

Reg. No. 16773

Sig:

Fax: (202) 822-0944
Tel: (202) 861-3503NOTE: File in duplicate with 2 postcard receipts (PAT-103) & attachments.

Frozen Food product5 Technical Field of the Invention

The invention relates to anti-freeze proteins (AFPs) and frozen food product containing AFPs.

10 Background to the Invention

Anti-freeze proteins (AFPs) have been suggested for improving the freezing tolerance of foodstuffs.

15 For the purpose of the invention, the term AFP has the meaning as well-known in the art, namely those proteins which exhibit the activity of inhibit the growth of ice crystals. See for example US 5,118,792.

20 WO 90/13571 discloses antifreeze peptides produced chemically or by recombinant DNA techniques. The AFPs can suitably be used in food-products.

WO 92/22581 discloses AFPs from plants which can be used
25 for controlling ice crystal shape in ice-cream. This document also describes a process for extracting a polypeptide composition from extracellular spaces of plants by infiltrating leaves with an extraction medium without rupturing the plants.

WO 94/03617 discloses the production of AFPs from yeast and their possible use in ice-cream. WO 96/11586 describes fish AFPs produced by microbes.

5 Several literature places also mention the isolation and/or use of plant proteins for cryoprotection. Cryoprotective proteins have a function in the protection of plant membranes against frost damage. These proteins, however, do not possess recrystallisation inhibition properties and
10 are, therefore, not embraced within the terms AFPs.

Hincha in Journal of Plant Physiology, 1992, 140, 236-240 describes the isolation of cryoprotective proteins from cabbage. Volger in Biochimica et Biophysica Acta, 412
15 (1975), 335-349 describes the isolation of cryoprotective leaf proteins from spinach. Boothe in Plant Physiol (1995), 108: 759-803 describes the isolation of proteins from Brassica napus. Again, these proteins are believed to be cryoprotective proteins rather than AFPs. Neven in Plant
20 Molecular Biology 21: 291-305, 1993 describes the DNA characterisation of a spinach cryoprotective protein. Salzman in Abstracts and Reviews of the 18th Annual Meeting of the ASEV/Eastern Section in Am. J. Enol. Vitic., Vol. 44, No. 4, 1993 describes the presence of boiling-stable
25 polypeptides in buds of Vitis. Although the proteins are analogous to fish antifreeze peptides, they are cryoprotective proteins and not AFPs. Lin in Biochemical and Biophysical Research Communication, Vol. 183, No. 3, 1992, pages 1103-1108 and in Lin, Plant Physiology (1992)
30 99, 519-525 describes the 15 kDa cryoprotective polypeptide from Arabidopsis Hakaira. Houde in The Plant Journal (1995) 8(4), 583-593 mentions cryoprotective proteins from wheat.

Up till now, however the use of AFPs has not been applied to commercially available food products. One reason for this are the high costs and complicated process for obtaining AFPs. Another reason is that the AFPs which until now have been suggested for use in frozen food products cannot be incorporated in the standard formulation mix, because they tend to destabilise during processing especially during the pasteurisation step. This destabilisation is believed to be caused by the denaturation of the AFPs; this is a well-known effect commonly observed for peptides and proteins.

In our non pre-published patent application: WO 98/4148 it has been described that particularly good AFPs can be isolated from natural sources such as Lichen.

Applicants have now been able to determine the partial amino acid sequence of a particularly active AFP from Lichen.

Accordingly the invention relates to an AFP which can be derived from Lichen, said AFP having an apparent molecular weight of about 24 kDa and an amino acid sequence from the N-terminus of:

A-P-A-W-M-D-A-E-S-F-G-A-I-A-H-G-G-L

Also embraced in the scope of our invention are proteins having a sequence which has a high degree of similarity with the above sequence. For the purpose of the invention all RI active proteins having an amino acid sequence of at least 80% overlap with the above sequence are also embraced

in the scope of the invention. More preferred is an overlap of at least 90%, most preferred more than 95%, e.g. those amino acid sequences which differ none or only one or two amino acids with the above sequence.

5

For the purpose of the invention the degree of overlap of two (partial) amino acid sequences can be calculated as follows:

- (a) the two amino acid sequences are aligned and the number of amino acids which are identical and appear in the same order are counted (X)
- (b) every change, deletion or addition of an amino acid is counted as 1 point, and the total of changes, deletions and additions is calculated (Y)
- (c) the degree of overlap can now be calculated as $X*100\%/(X+Y)$.

For example the (partial) amino acid sequence from the N-terminus of:

- A-P-A-V-V-M-G-D-A-E-S-F-G-A-I-A-H-G-G-L, can be aligned with the control as follows:

A-P-A-V-V-M-G-D-A-E-S-F-G-A-I-A-H-G-G-L

A-P-A-W -M- D-A-E-S-F-G-A-I-A-H-G-G-L

25

- This leads to a total number of identical amino acids in the same order of 17. The number of changes is 1 (W into V at the fourth position); the number of additions is 2 (V at fifth position, G at 7th position), while there are no deletions. The total of changes, additions and deletions is therefore 3. This leads to a degree of overlap of $17*100\%/(17+3) = 85\%$

The protein having (partial) amino acid sequence from the N-terminus of:

A-P-A-V-V-M-G-D-A-E-S-F-G-A-I-A-H-G-G-L is hence also embraced within the invention.

5

Also embraced within the scope of the present invention are modified versions of the above described proteins whereby said modification does not materially affect the ice recrystallisation inhibition properties, such as
10 glycosylated versions thereof.

For the purpose of the invention the term about 24 kDa molecular weight means any molecular weight from 20 to 28 kDa as measured on SDS-PAGE using standard reference
15 markers, more preferably the molecular weight is from 22 to 26 kDa.

The advantageous AFP of the present invention can be derived from Lichen especially from the species *Umbilicaria*
20 *antarctica*.

Also embraced within the scope of the present invention are anti-freeze proteins which although originally derived from Lichen are produced by other methods, for example by
25 genetic modification techniques whereby for example microorganisms or plants are genetically modified to produce the above described proteins. These proteins are also embraced within the term "can be derived from Lichen".

30 Also embraced within the scope of the present are nucleic acid sequences which are capable to encode the above described AFPs.

Vectors containing a nucleic acid sequence capable of encoding the AFP of the invention are also embraced within the scope of the invention.

5

Based on the above information it is also possible to genetically modify other natural sources such that they produce the advantageous AFP as identified here-above.

10

Applicants also have found that AFPs of the above sequence have improved ice-recrystallisation inhibition properties. A suitable test for determining the ice recrystallisation inhibition properties is described in the examples and involves the quick freezing to at least -40°C, for example -80°C followed by storage for one hour at -60°C. Preferably AFPs in accordance to the invention provide a ice particle size following an ice recrystallisation inhibition assay - as described in the examples- of 15 µm or less, more preferred from 5 to 15 µm.

The AFP of the invention can conveniently be used in food products, preferably in food products which are frozen or intended to be frozen. Especially preferred is the use of AFPs in products which are heated e.g. by pasteurisation or sterilisation prior to freezing. Especially preferred is the use in frozen confectionery products.

Examples of such food products are: frozen confectionery mixes such as ice-cream mixes and water-ice mixes which are intended to be pasteurised prior to freezing. Such mixes

are usually stored at ambient temperature. Suitable product forms are for example: a powder mix which is packed for example in a bag or in sachets. Said mix being capable of forming the basis of the frozen food product e.g. after addition of water and optionally other ingredients and - optional- aeration.

Another example of a suitable mix could be a liquid mix (optionally aerated) which, if necessary after addition of further components and optional further aeration can be frozen.

The clear advantage of the above mentioned mixes is that the presence of the AFP ingredient makes that the mixes can be frozen under quiescent conditions, for example in a shop or home freezer without the formation of unacceptable ice crystal shapes and hence with a texture different to products normally obtained via quiescent freezing.

Very conveniently these mixes are packed in closed containers (e.g. cartons, bags, boxes, plastic containers etc). For single portions the pack size will generally be from 10 to 1000 g. For multiple portions pack sizes of up to 500 kg may be suitable. Generally the pack size will be from 10 g to 5000 g.

As indicated above the preferred products wherein the AFPs are used are frozen confectionery product such as ice-cream or water-ice. Preferably the level of AFPs is from 0.00001 to 0.5 wt% based on the final product. If dry-mixes or concentrates are used, the concentration may be higher in

order to ensure that the level in the final frozen product is within the above ranges.

For the purpose of the invention the term frozen
5 confectionery product includes milk containing frozen confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees. For some applications the use in fermented food products is less preferred.

10 Preferably a the level of solids in the frozen confection (e.g. sugar, fat, flavouring etc) is more than 4 wt%, for example more than 30 wt%, more preferred from 40 to 70wt%.

15 Frozen confectionery products according to the invention can be produced by any method suitable for the production of frozen confectionery. Especially preferably however all the ingredients of the formulation are fully mixed before pasteurisation and before the freezing process starts. The
20 freezing process may advantageously involve a hardening step, for example to a temperature of -30 Fahrenheit or lower.

Example I

The ice recrystallisation inhibition properties of the AFPs can determined as follows:

5 A sample of an AFP containing product was adjusted to a sucrose level of 30 wt% (If the starting level of the sample was more than 30% this was done by dilution, if the starting level was lower sucrose was added to the 30% level).

10

A 3 μ L drop of the sample was placed on a 22 mm coverslip. A 16 mm diameter cover-slip was then placed on top and a 200 g weight was placed on the sample to ensure a uniform slide thickness. The edges of the coverslip were sealed
15 with clear nail varnish.

The slide was placed on a Linkham THM 600 temperature controlled microscope stage. the stage was cooled rapidly (50 $^{\circ}$ C per minute) to -40 $^{\circ}$ C to produce a large population
20 of small crystals. The stage temperature was then raised rapidly (50 $^{\circ}$ C per minute) to -6 $^{\circ}$ C and held at this temperature.

The ice-phase was observed at -6 $^{\circ}$ C using a Leica
25 Aristoplan microscope. Polarised light conditions in conjunction with a lambda plate were used to enhance the contrast of the ice crystals. The state of the ice phase (size of ice crystals) was recorded by 35 mm photomicrography at T=0 and T=1 hour. The ice-crystal size
30 (length) was determined by drawing around the perimeter of the crystals. The maximum length for each individual ice crystal of a batch of ice cream was imported into a

spreadsheet where analysis of the data set was carried out to find the mean, and standard deviation.

Another method to test ice recrystallisation inhibition properties is as follows:

Anti-freeze activity was measured using a modified "splat assay" (Knight et al, 1988). 2.5 μ l of the solution under investigation in 30% (w/w) sucrose was transferred onto a clean, appropriately labelled, 16 mm circular coverslip. A second coverslip was placed on top of the drop of solution and the sandwich pressed together between finger and thumb. The sandwich was dropped into a bath of hexane held at -80°C in a box of dry ice. When all sandwiches had been prepared, sandwiches were transferred from the -80°C hexane bath to the viewing chamber containing hexane held at -6°C using forceps pre-cooled in the dry ice. Upon transfer to -6°C , sandwiches could be seen to change from a transparent to an opaque appearance. Images were recorded by video camera and grabbed into an image analysis system (LUCIA, Nikon) using a 20x objective. Images of each splat were recorded at time = 0 and again after 30-60 minutes. The size of the ice-crystals in both assays was compared. If the size at 30-60 minutes is similar or only moderately increased (say less than 20% increased, more preferred less than 10% increased, most preferred less than 5 % increased) compared to the size at $t=0$, this is an indication of good ice-crystal recrystallisation inhibition properties.

Generally these tests can be applied to any suitable composition comprising AFP and water. Generally the level of AFP in such a test composition is not very critical and can for example be from 0.0001 to 0.5 wt%, more preferred 5 0.0005 to 0.1 wt%, most preferred 0.001 to 0.05 wt%, for example 0.01 wt%

Any suitable composition comprising AFP and water can be used to carry out the test. Generally, however, it will not 10 be necessary to obtain the AFP in purified form. For practical applications normally it would suffice to prepare a liquid extract or juice of natural material, wherein this extract or juice can then be tested.

Example II

9.5 g *Umbilicaria antarctica* collected during Spring 1996 from the Antarctic and stored at -20 C was homogenised in liquid nitrogen in a mortar and pestle to a fine powder. This powder was transferred to a fresh mortar and pestle held at room temperature. Following the addition of 10 ml 0.2 M Tris HCl containing 10 mM EDTA the powder was further ground in the mortar and pestle and the homogenate filtered through 2 layers of muslin. The retentate was replaced in the mortar and pestle and a further 10 ml buffer added and the retentate ground further. This material was filtered as above and the filtrate pooled with filtrate from the first homogenisation step. The filtrate was centrifuged at 30,000 g for 15 minutes and the supernatant collected and frozen in aliquots.

0.15 g NH_4SO_4 was dissolved in 1ml supernatant and the solution incubated for 30 minutes at 4 C. After centrifugation at 30,000 g for 10 minutes 0.3 g NH_4SO_4 was dissolved in the supernatant from this step and the solution incubated at 4 C for 30 minutes. The solution was centrifuged at 30,000 g for 10 minutes and the supernatant discarded. The pellet was resuspended in 0.2 ml water and serial dilutions of this solution and the original extract prepared in 30 % (w/w) sucrose in water for semi-quantitative splat analysis. Splat activity could be detected (by the above method) in the original extract to a dilution of more than 200 fold and in the resuspended pellet to a dilution of 800 fold indicating that more than

half of the total splat activity present in the original extract had been harvested in the NH_4SO_4 pellet.

200 microlitre 0.1 M TrisHCl pH 7.5 was added to the resuspended pellet and the solution concentrated in a 10 kDa cut-off microcon (Amicon) to 150 microlitre. 100 microlitre of this solution was applied to a Q-Sepharose column pre-equilibrated in 50 mM Tris HCl pH 7.5 using a SMART chromatography system (Pharmacia) at a flow rate of 100 microlitre per minute and 100 microlitre fractions collected. Following 800 microlitre was in 50 mM Tris HCl pH 7.5, a 0-0.5 M NaCl gradient was applied to the column over 1.5 ml and the eluate monitored at 280 nm. Following 50 fold dilution in 30 w/w % sucrose, fractions were tested for splat activity as in example I. Activity was found to correlate with a peak of OD 280 which eluted at approximately 0.1 M NaCl which was mainly collected in fraction 14.

40 microlitre fraction 14 was applied to a Superdex 75 gel permeation column pre-equilibrated in 50 mM Tris HCl pH 7.5 at a flow rate of 40 microlitre per minute using a SMART chromatography system (Pharmacia). The eluate was monitored at OD 280 and OD 215 and the 80 microlitre fractions were collected from 0.6 ml after sample application, 50 microlitre fractions between 1.1 and 1.6 ml and 100 microlitre fractions between 1.6 and 3 ml. 1 microlitre from each fraction was diluted 25 times in 30 w/w% sucrose and assayed for splat activity. Activity was found to correlate with a peak of OD280 and OD215 which eluted with a retention of 1.2 ml in fractions 9 and 10. The Superdex column was calibrated by determination of the retention

volume (V_e) of standard protein molecular weight markers (Sigma) and the void volume (V_o) determined as 0.91 ml by application of blue dextran. A standard curve of $\log_{10} M_r$ against V_e/V_o was plotted and the apparent molecular weight of the OD 280 peak correlating with the lichen splat activity determined as 30 kDa.

32 microlitre from fractions 9 and 10 eluting from the Superdex column were pooled and concentrated to 10 microlitre in a 10 kDa cut-off microcom (Amicon) and 3.5 microlitre 4x SDS-PAGE sample buffer was added to 10 microlitre fractions 9 and 10 eluting from the Superdex column and to fractions 12-16 eluting from the Q-sepharose column. Following heating 95 C for five minutes and centrifugation at 10,000 g for 3 minutes 10 microlitres of each sample was loaded into wells in a 4% stacking gel and polypeptides separated by electrophoresis through a 12% 0.75 mm thick SDS-PAGE mini-gel (Biorad). Following electrophoresis the gel was stained and fixed in Coomassie Brilliant Blue and destained in methanol:acetic acid:water (1:4:5) w/w. This revealed a polypeptide of apparent M_r 24 kDa in the concentrated pooled fractions 9 and 10 eluting from the Superdex column. When the gel was silver stained using the Biorad silver stain kit according to the manufacturers instructions, a polypeptide with the same apparent M_r was detectable in fraction 14 eluting from the Q-Sepharose column and in fractions 9 and 10 eluting from the Superdex column.

Following purification of further protein using essentially the same methodology as described above, the following N-

terminal amino-acid sequence was obtained from the 24 kDa polypeptide:

A-P-A-V-V-M-G-D-A-E-S-F-G-A-I-A-H-G-G-L

5

Example III

Crude lichen filtrate in accordance to example II was ammonium sulphate precipitated and resuspended in 0.2M Tris/HCl pH 7.5 as described above and then diluted 1/10 into one of the following buffers: 0.2M sodium citrate pH 3.0, 0.2M sodium acetate pH 4.0, 0.2M Piperazine pH 5.0, 0.2 M bisTris pH 6.0, 0.2 M triethanolamine pH 7.0, 0.2 M Tris pH 8.0, 0.2 M CHES pH 9.0, 0.2 M CAPS pH 10.0. These samples were then serially diluted 1/2 in the relevant buffer and the dilutions mixed 1:1 with 60% sucrose prior to splat analysis according to the second test as described in example I. Between pH 10 and pH 6.0 recrystallisation inhibition activity could be detected clearly down to a dilution of 1/320. Between pH 3.0 - 5.0 activity could be clearly detected to a dilution of 1/80 indicating that although the protein retains some activity at low pH, its activity is reduced by a factor of 4 at pH at or below 5.0.

25 Example IV

Purified lichen antifreeze in accordance to example II protein was separated by 2 dimensional electrophoresis. Gel containing 9.2M urea, 4% acrylamide (2.66ml 30% acrylamide 0.8% bisacrylamide), 2% deionised Triton X 100, 1% 4-7 Bio-lyte ampholyte (Biorad), 1% 3.5-10 Bio-lyte ampholyte (Biorad), 0.1% TEMED, 0.01% ammonium persulphate was

polymerised in small glass tubes (Biorad). The tubes were rinsed in distilled water and inserted into a mini-gel system capable of accommodating them and the upper chamber filled with 20mM NaOH and the lower chamber with 10mM H_3PO_4 .

5 Purified lichen sample was mixed 1:1 with first dimension sample buffer (9.2 M urea, 2.0% Triton X-100, 5% beta-mercaptoethanol, 1% 4-7 Bio-lyte ampholyte, 0.25% 3-10 Bio-lyte ampholyte) and warmed to 37°C prior to application to one of the tube gels. To a second rod, 2 dimensional marker

10 proteins (Biorad) were applied and to a third rod a mixture of 2 dimensional marker proteins and the lichen sample was applied. Following electrophoresis at 500V for 10 minutes and 750 V for 4 hours the rods were extruded from the tubes and loaded onto 3 separate 1mm thick 12% SDS-PAGE mini gels

15 (Biorad) and overlayed with SDS-PAGE sample buffer. Following electrophoresis the gels were silver stained using the Biorad kit according to the manufacturer's instructions. The separation revealed 3 spots on the gel in the lichen sample all with an apparent Mr of approximately

20 24 kDa and PI lower than 4.5.

1 dimensional isoelectric focussing of purified lichen antifreeze protein using a slab gel composed of the same components as in the first dimension gel in the 2

25 dimensional separation except Biolyte 3-5 ampholytes were used in the place of Biolyte 4-7 ampholytes revealed a band with an isoelectric point lower than 3.6 following silver staining.

Claims

1. Anti-freeze protein which can be derived from Lichen, said protein having an apparent molecular weight of from 20 to 28 kDa and having an N-terminal amino acid sequence which shows at least 80% overlap with:
A-P-A-W-M-D-A-E-S-F-G-A-I-A-H-G-G-L
and modified versions and isoforms of this protein
2. Anti-freeze protein of claim 1 having an N-terminal amino acid sequence as follows:
A-P-A-V-V-M-G-D-A-E-S-F-G-A-I-A-H-G-G-L
and modified versions and isoforms of this protein.
3. Anti-freeze protein of claim 1 or 2, having a molecular weight of from 22 to 26 kDa.
4. Anti-freeze protein of claim 1 or 2, showing at least 90% overlap with the partial sequences of claim 1 or 2.
5. Anti-freeze protein of claim 1 or 2, showing 100% overlap with the partial sequences of claim 1 or claim 2.
6. Anti-freeze protein of claim 1, wherein the modification involves glycosylation.
7. Nucleic acid sequence encoding the anti-freeze protein of one or more of the preceding claims.

**FOR UTILITY/DESIGN
CIP/PCT NATIONAL/PLANT
ORIGINAL/SUBSTITUTE/SUPPLEMENTAL
DECLARATIONS**

**RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**CUSHMAN
FORM**

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the INVENTION ENTITLED:

ANTIFREEZE PROTEIN

the specification of which (CHECK applicable BOX(ES))

X ☐ is attached hereto
[X] was filed on 23 June 2000 as U.S. Application No. 09/582,296
Box(es) ☐ was filed as PCT International Application No. _____ on _____
and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 25 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application:

PRIOR FOREIGN APPLICATION(S)		Date First Laid - open or Published	Date Patented or granted	Priority Claimed Yes No
Number	Country	Day/MONTH/Year Filed		
9801420.2	GB	22 January 1998		YES

I hereby claim domestic priority benefit under 35 U.S.C. 120/365 of the indicated United States applications listed below and PCT international applications listed above or below and, if this is a continuation-in-part (CIP) application, insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application:

PRIOR U.S. PROVISIONAL, NONPROVISIONAL AND/OR PCT APPLICATION(S)		Status	Priority Claimed Yes No
Application Number (series code/serial no.)	Day/MONTH/Year Filed	pending, abandoned, patented	
PCT/EP98/08554	23 DECEMBER 1998	PENDING	YES

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Cushman Darby & Cushman Intellectual Property Group of Pillsbury Madison & Sutro L.L.P. 1100 New York Avenue, N.W., Ninth Floor, East Tower, Washington D.C. 20005-3918, telephone number (202) 861-3000 (to whom all communications are to be directed), and the below-named persons (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent, and I hereby authorize them to delete names/numbers below of persons no longer with their firm and to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above Firm and/or a below attorney in writing to the contrary.

Paul N. Kokulis	16273	David W. Brinkman	20817	Chris Comuntzis	31097	David A. Jakopin	32995
Raymond F. Lippitt	17519	George M. Sirilla	18221	Lawrence Harbin	27644	Mark G. Paulson	30793
G. Lloyd Knight	17698	Donald J. Bird	25323	Paul E. White Jr.	32011	James D. Berquist	34776
Carl G. Love	18781	W. Warren Taltavull	25647	Michelle N. Lester	32331	Timothy J. Klima	34852
Edgar H. Martin	20534	Peter W. Gowdey	25872	Jeffrey A. Simenauer	31993	John P. Moran	30906
William K. West, Jr.	22057	Dale S. Lazar	28872	Robert A. Molan	29834	Stephen C. Glazier	31361
Kevin E. Joyce	20508	Glenn J. Perry	28458	G. Paul Edgell	24238	Paul F. McQuade	31542
Edward M. Prince	22429	Kendrew H. Colton	30368	Lynn E. Eccleston	35861		

1) INVENTOR'S SIGNATURE: Christopher M. Satchell Date 25/08/00
Inventor's Name (typed) Christopher M. Satchell SIDEBOTTOM UNITED KINGDOM
First Middle Initial Family Name Country of Citizenship

Residence (City) BEDFORD (State/Foreign Country) UNITED KINGDOM GBR
Post Office Address (Include Zip Code) c/o Unilever Research Colworth, Colworth House, Sharnbrook, Bedford, MK44 1LQ, United Kingdom

2) INVENTOR'S SIGNATURE: Margaret F. Smallwood Date 15/09/00
Inventor's Name (typed) Margaret F. Smallwood SMALLWOOD UNITED KINGDOM
First Middle Initial Family Name Country of Citizenship

Residence (City) York (State/Foreign Country) UNITED KINGDOM GBR
Post Office Address (Include Zip Code) c/o The University of York, Department of Biology, P O Box No. 373, York, YO10 5YW, United Kingdom

3) INVENTOR'S SIGNATURE: Louise J. Byass Date 16.11.00
Inventor's Name (typed) Louise J. Byass BYASS UNITED KINGDOM
First Middle Initial Family Name Country of Citizenship

Residence (City) EDMONTON (State/Foreign Country) CANADA CAX
Post Office Address (Include Zip Code) c/o university of Alberta, 4-10 Agriculture/Forestry Centre, Edmonton, Alberta, T6G 2P5, Canada

Rule 56(a) & (b) = 37 C.F.R. 1.56(a) & (b)
PATENT AND TRADEMARK CASES - RULES OF PRACTICE
DUTY OF DISCLOSURE

- (a) ...Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the [Patent and Trademark] Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability ... (b) information is material to patentability when it is not cumulative and (1) It also establishes by itself, or in combination with other information, a prima facie case of unpatentability of a claim or (2) refers, or is inconsistent with, a position the applicant takes in (i) Opposing an argument of unpatentability relied on by the Office, or (ii) Asserting an argument of patentability.

PATENT LAWS 35 U.S.C.

§102. Conditions for patentability; novelty and loss of right to patent

A person shall be entitled to a patent unless--

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent or
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or
- (c) he has abandoned the invention, or
- (d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months* before the filing of the application in the United States, or
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent, or
- (f) he did not himself invent the subject matter sought to be patented, or
- (g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

§103. Conditions for patentability; non-obvious subject matter

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which the said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made. Subject matter developed by another person, which qualified as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

* Six months for Design Applications (35 U.S.C. 172).